Piramal Pharma reports a swing to profit in its latest quarter, with revenue rising and the company citing improved performance in its operating results. Business Line and NDTV both say the quarter marks a shift from earlier performance, and that the company uses the results to strengthen its forward-looking view.

Across outlets, the emphasis differs on what is driving the upgrade. NDTV highlights Piramal Pharma’s CDMO business as the key growth driver, pointing to strong order inflows and execution that lift CDMO revenue growth during the quarter. Business Line also frames the story around improved earnings and an upgraded outlook, while noting that the company is looking for a stronger second half of the year and has raised its growth guidance for the fiscal period ahead.

Together, the coverage presents a consistent picture: quarterly profitability improves, growth accelerates, and management raises expectations for revenue growth and the year ahead, with market reaction mentioned by Business Line in one report.